Advertisement Helix BioPharma announces completion of private placement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Helix BioPharma announces completion of private placement

BioPharma, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, has announced it has completed a private placement with net proceeds in excess of CAD5.4 million, after fees and expenses associated with the placement.

The terms of the placement are for the purchase of common shares at $1.60 per share and include one warrant per share at an exercise price of $2.24 and have an expiry of five years from the date of issue.

"We expect that these funds will allow us to complete the Phase I component of the Polish trial and all the preparatory work required for the previously approved US Phase I clinical trial of L-DOS47 in combination with Pemetrexed and Carboplatin", stated Robert Verhagen, President & CEO of Helix.

ACM Alpha Management Consulting Est. provided financial advisory services to Helix in connection with this private placement.